PUBLISHER: Persistence Market Research | PRODUCT CODE: 1776819
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1776819
Neuropathic Pain Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Persistence Market Research has recently released a comprehensive report on the worldwide market for neuropathic pain treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neuropathic pain market from 2025 to 2032.
Key Insights:
- Neuropathic Pain Market Size (2025E): USD 9.1 Billion
- Projected Market Value (2032F): USD 13.2 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 5.5%
Neuropathic Pain Market - Report Scope:
Neuropathic pain treatment targets chronic pain conditions caused by nerve damage or dysfunction, including diabetic neuropathy, post-herpetic neuralgia, spinal cord injury, multiple sclerosis, and chemotherapy-induced neuropathy. The market encompasses pharmaceutical interventions such as antidepressants, anticonvulsants, topical agents, and opioids, as well as non-pharmacological approaches including neuromodulation and physical therapy. The increasing burden of chronic pain and neurological disorders globally has led to a growing demand for targeted and effective neuropathic pain treatments across hospitals, pain clinics, and homecare settings.
Market Growth Drivers:
The global neuropathic pain market is propelled by the rising prevalence of diabetes, cancer, and other chronic conditions that are strongly associated with nerve damage. Aging populations and sedentary lifestyles further contribute to the increased incidence of neuropathic conditions. Growing awareness among healthcare professionals and patients regarding the debilitating effects of neuropathic pain and the availability of specialized treatments is fostering market growth. Moreover, advancements in pharmacological research have led to the development of novel therapeutics with better efficacy and tolerability, enhancing patient adherence and outcomes. The adoption of combination therapy and targeted drug delivery systems is also gaining momentum, offering improved management of complex pain syndromes.
Market Restraints:
Despite the growing demand, the neuropathic pain market faces several challenges, including limited effectiveness of existing medications, high risk of side effects, and dependence associated with long-term use of opioids. Reimbursement limitations, especially in developing regions, further restrict access to high-cost treatments such as neuromodulation devices or branded pharmaceuticals. Additionally, clinical trials for neuropathic pain often face difficulties in patient recruitment and outcome variability, delaying drug approvals and innovation timelines. Regulatory complexities and the need for robust evidence supporting long-term safety and efficacy continue to pose significant hurdles for market participants.
Market Opportunities:
The neuropathic pain market presents substantial growth opportunities driven by advancements in personalized medicine, biologics, and neurostimulation technologies. Research into gene therapy, RNA-based treatments, and regenerative medicine holds promise for more effective and long-lasting pain relief. Increasing investment in digital therapeutics and AI-driven pain management platforms enables real-time monitoring, early intervention, and enhanced patient engagement. Moreover, strategic collaborations among pharmaceutical companies, research institutions, and biotech firms are accelerating the pipeline of next-generation neuropathic pain solutions. Expansion into emerging markets with improving healthcare infrastructure and rising disease awareness offers new revenue streams for market players.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the neuropathic pain market globally?
- Which treatment modalities and drug classes are leading the adoption of neuropathic pain therapies?
- How are technological advancements reshaping the competitive landscape of the neuropathic pain market?
- Who are the key players contributing to the neuropathic pain market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global neuropathic pain treatment landscape?
Competitive Intelligence and Business Strategy:
These companies invest in next-generation analgesics, including sodium channel blockers, TRPV1 antagonists, and monoclonal antibodies to overcome limitations of existing therapies. Collaborative research initiatives and acquisitions aimed at enhancing R&D capabilities and expanding therapeutic portfolios are key strategies. Additionally, companies are emphasizing patient-centric approaches, digital engagement tools, and education campaigns to support diagnosis, treatment adherence, and quality of life improvements.
Key Companies Profiled:
- Almatica
- Vertex Pharmaceuticals Incorporated
- Azurity Pharmaceuticals, Inc.
- Pfizer Inc.
- Viatris Inc.
- Supernus Pharmaceuticals, Inc.
- Novartis AG
- Accord Healthcare
- Focus Health Group
- Amneal Pharmaceuticals LLC
- Abbott
- Teva Pharmaceutical Industries Ltd.
- Others
Neuropathic Pain Market Research Segmentation:
The neuropathic pain market encompasses a diverse range of drug classes, indications, treatment approaches, and end-user segments.
By Drug Class
- Tricyclic Anti-Depressants
- Anticonvulsants
- SNRI's
- Topical Anesthetics
- Opioids
- Others
By Indication
- Diabetic Neuropathy
- Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- Post-Herpetic Neuralgia (PHN)
- Trigeminal Neuralgia
- Spinal Cord Injury-Associated Neuropathy
- Phantom Limb Pain
- Multiple Sclerosis-Associated Neuropathy
- Others
By Route of Administration
- Oral
- Topical
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Neuropathic Pain Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. COVID-19 Impact Analysis
- 2.4. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Disease Epidemiology
- 3.2. Value Chain Analysis
- 3.3. Technology Assessment
- 3.4. Product Adoption / Usage Analysis
- 3.5. Recent Product Approvals & Launches
- 3.6. Key Market Players
- 3.7. Regulatory Landscape
- 3.8. PESTLE Analysis
- 3.9. Porter's Five Force Analysis
4. Global Neuropathic Pain Market Outlook
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Neuropathic Pain Market Outlook: Drug Class
- 4.3.1. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
- 4.3.2. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 4.3.2.1. Tricyclic Anti-Depressants
- 4.3.2.2. Anticonvulsants
- 4.3.2.3. SNRI's
- 4.3.2.4. Topical Anesthetics
- 4.3.2.5. Opioids
- 4.3.2.6. Others
- 4.3.3. Market Attractiveness Analysis: Drug Class
- 4.4. Global Neuropathic Pain Market Outlook: Indication
- 4.4.1. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
- 4.4.2. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 4.4.2.1. Diabetic Neuropathy
- 4.4.2.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 4.4.2.3. Post-Herpetic Neuralgia (PHN)
- 4.4.2.4. Trigeminal Neuralgia
- 4.4.2.5. Spinal Cord Injury-Associated Neuropathy
- 4.4.2.6. Phantom Limb Pain
- 4.4.2.7. Multiple Sclerosis-Associated Neuropathy
- 4.4.2.8. Others
- 4.4.3. Market Attractiveness Analysis: Indication
- 4.5. Global Neuropathic Pain Market Outlook: Route of Administration
- 4.5.1. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
- 4.5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 4.5.2.1. Oral
- 4.5.2.2. Topical
- 4.5.2.3. Parenteral
- 4.5.3. Market Attractiveness Analysis: Route of Administration
- 4.6. Global Neuropathic Pain Market Outlook: Distribution Channel
- 4.6.1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
- 4.6.2. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 4.6.2.1. Hospital Pharmacies
- 4.6.2.2. Retail Pharmacies
- 4.6.2.3. Online Pharmacies
- 4.6.3. Market Attractiveness Analysis: Distribution Channel
5. Global Neuropathic Pain Market Outlook: Region
- 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.2. Current Market Size (US$ Bn) and Forecast Analysis, By Region, 2025-2032
- 5.2.1. North America
- 5.2.2. Latin America
- 5.2.3. Europe
- 5.2.4. East Asia
- 5.2.5. South Asia and Oceania
- 5.2.6. Middle East & Africa
- 5.3. Market Attractiveness Analysis: Region
6. North America Neuropathic Pain Market Outlook
- 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.1.1. By Country
- 6.1.2. By Drug Class
- 6.1.3. By Indication
- 6.1.4. By Route of Administration
- 6.1.5. By Distribution Channel
- 6.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 6.2.1. U.S.
- 6.2.2. Canada
- 6.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 6.3.1. Tricyclic Anti-Depressants
- 6.3.2. Anticonvulsants
- 6.3.3. SNRI's
- 6.3.4. Topical Anesthetics
- 6.3.5. Opioids
- 6.3.6. Others
- 6.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 6.4.1. Diabetic Neuropathy
- 6.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 6.4.3. Post-Herpetic Neuralgia (PHN)
- 6.4.4. Trigeminal Neuralgia
- 6.4.5. Spinal Cord Injury-Associated Neuropathy
- 6.4.6. Phantom Limb Pain
- 6.4.7. Multiple Sclerosis-Associated Neuropathy
- 6.4.8. Others
- 6.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 6.5.1. Oral
- 6.5.2. Topical
- 6.5.3. Parenteral
- 6.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies
- 6.6.3. Online Pharmacies
- 6.7. Market Attractiveness Analysis
7. Europe Neuropathic Pain Market Outlook
- 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.1.1. By Country
- 7.1.2. By Drug Class
- 7.1.3. By Indication
- 7.1.4. By Route of Administration
- 7.1.5. By Distribution Channel
- 7.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 7.2.1. Germany
- 7.2.2. France
- 7.2.3. U.K.
- 7.2.4. Italy
- 7.2.5. Spain
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 7.3.1. Tricyclic Anti-Depressants
- 7.3.2. Anticonvulsants
- 7.3.3. SNRI's
- 7.3.4. Topical Anesthetics
- 7.3.5. Opioids
- 7.3.6. Others
- 7.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 7.4.1. Diabetic Neuropathy
- 7.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 7.4.3. Post-Herpetic Neuralgia (PHN)
- 7.4.4. Trigeminal Neuralgia
- 7.4.5. Spinal Cord Injury-Associated Neuropathy
- 7.4.6. Phantom Limb Pain
- 7.4.7. Multiple Sclerosis-Associated Neuropathy
- 7.4.8. Others
- 7.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 7.5.1. Oral
- 7.5.2. Topical
- 7.5.3. Parenteral
- 7.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies
- 7.6.3. Online Pharmacies
- 7.7. Market Attractiveness Analysis
8. East Asia Neuropathic Pain Market Outlook
- 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.1.1. By Country
- 8.1.2. By Drug Class
- 8.1.3. By Indication
- 8.1.4. By Route of Administration
- 8.1.5. By Distribution Channel
- 8.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 8.2.1. China
- 8.2.2. Japan
- 8.2.3. South Korea
- 8.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 8.3.1. Tricyclic Anti-Depressants
- 8.3.2. Anticonvulsants
- 8.3.3. SNRI's
- 8.3.4. Topical Anesthetics
- 8.3.5. Opioids
- 8.3.6. Others
- 8.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 8.4.1. Diabetic Neuropathy
- 8.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 8.4.3. Post-Herpetic Neuralgia (PHN)
- 8.4.4. Trigeminal Neuralgia
- 8.4.5. Spinal Cord Injury-Associated Neuropathy
- 8.4.6. Phantom Limb Pain
- 8.4.7. Multiple Sclerosis-Associated Neuropathy
- 8.4.8. Others
- 8.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 8.5.1. Oral
- 8.5.2. Topical
- 8.5.3. Parenteral
- 8.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies
- 8.6.3. Online Pharmacies
- 8.7. Market Attractiveness Analysis
9. South Asia & Oceania Neuropathic Pain Market Outlook
- 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.1.1. By Country
- 9.1.2. By Drug Class
- 9.1.3. By Indication
- 9.1.4. By Route of Administration
- 9.1.5. By Distribution Channel
- 9.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 9.2.1. India
- 9.2.2. Indonesia
- 9.2.3. Thailand
- 9.2.4. Singapore
- 9.2.5. ANZ
- 9.2.6. Rest of South Asia & Oceania
- 9.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 9.3.1. Tricyclic Anti-Depressants
- 9.3.2. Anticonvulsants
- 9.3.3. SNRI's
- 9.3.4. Topical Anesthetics
- 9.3.5. Opioids
- 9.3.6. Others
- 9.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 9.4.1. Diabetic Neuropathy
- 9.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 9.4.3. Post-Herpetic Neuralgia (PHN)
- 9.4.4. Trigeminal Neuralgia
- 9.4.5. Spinal Cord Injury-Associated Neuropathy
- 9.4.6. Phantom Limb Pain
- 9.4.7. Multiple Sclerosis-Associated Neuropathy
- 9.4.8. Others
- 9.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 9.5.1. Oral
- 9.5.2. Topical
- 9.5.3. Parenteral
- 9.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies
- 9.6.3. Online Pharmacies
- 9.7. Market Attractiveness Analysis
10. Latin America Neuropathic Pain Market Outlook
- 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.1.1. By Country
- 10.1.2. By Drug Class
- 10.1.3. By Indication
- 10.1.4. By Route of Administration
- 10.1.5. By Distribution Channel
- 10.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 10.2.1. Brazil
- 10.2.2. Mexico
- 10.2.3. Rest of Latin America
- 10.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 10.3.1. Tricyclic Anti-Depressants
- 10.3.2. Anticonvulsants
- 10.3.3. SNRI's
- 10.3.4. Topical Anesthetics
- 10.3.5. Opioids
- 10.3.6. Others
- 10.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 10.4.1. Diabetic Neuropathy
- 10.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 10.4.3. Post-Herpetic Neuralgia (PHN)
- 10.4.4. Trigeminal Neuralgia
- 10.4.5. Spinal Cord Injury-Associated Neuropathy
- 10.4.6. Phantom Limb Pain
- 10.4.7. Multiple Sclerosis-Associated Neuropathy
- 10.4.8. Others
- 10.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 10.5.1. Oral
- 10.5.2. Topical
- 10.5.3. Parenteral
- 10.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies
- 10.6.3. Online Pharmacies
- 10.7. Market Attractiveness Analysis
11. Middle East & Africa Neuropathic Pain Market Outlook
- 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.1.1. By Country
- 11.1.2. By Drug Class
- 11.1.3. By Indication
- 11.1.4. By Route of Administration
- 11.1.5. By Distribution Channel
- 11.2. Current Market Size (US$ Bn) Analysis and Forecast by Country, 2025-2032
- 11.2.1. GCC Countries
- 11.2.2. Egypt
- 11.2.3. South Africa
- 11.2.4. Northern Africa
- 11.2.5. Rest of Middle East & Africa
- 11.3. Current Market Size (US$ Bn) and Forecast Analysis, By Drug Class, 2025-2032
- 11.3.1. Tricyclic Anti-Depressants
- 11.3.2. Anticonvulsants
- 11.3.3. SNRI's
- 11.3.4. Topical Anesthetics
- 11.3.5. Opioids
- 11.3.6. Others
- 11.4. Current Market Size (US$ Bn) and Forecast Analysis, By Indication, 2025-2032
- 11.4.1. Diabetic Neuropathy
- 11.4.2. Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- 11.4.3. Post-Herpetic Neuralgia (PHN)
- 11.4.4. Trigeminal Neuralgia
- 11.4.5. Spinal Cord Injury-Associated Neuropathy
- 11.4.6. Phantom Limb Pain
- 11.4.7. Multiple Sclerosis-Associated Neuropathy
- 11.4.8. Others
- 11.5. Current Market Size (US$ Bn) and Forecast Analysis, By Route of Administration, 2025-2032
- 11.5.1. Oral
- 11.5.2. Topical
- 11.5.3. Parenteral
- 11.6. Current Market Size (US$ Bn) and Forecast Analysis, By Distribution Channel, 2025-2032
- 11.6.1. Hospital Pharmacies
- 11.6.2. Retail Pharmacies
- 11.6.3. Online Pharmacies
- 11.7. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping by Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Almatica
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Sources
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Vertex Pharmaceuticals Incorporated
- 12.3.3. Azurity Pharmaceuticals, Inc.
- 12.3.4. Pfizer Inc.
- 12.3.5. Viatris Inc.
- 12.3.6. Supernus Pharmaceuticals, Inc.
- 12.3.7. Novartis AG
- 12.3.8. Accord Healthcare
- 12.3.9. Focus Health Group
- 12.3.10. ABneal Pharmaceuticals LLC.
- 12.3.11. Abbott
- 12.3.12. Teva Pharmaceutical Industries Ltd.
- 12.3.13. Others
- 12.3.1. Almatica
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
